Thus, nanomedicine targeting CD44 in GBM to deliver anti‐PLD1 drugs or natural anti‐cancer molecules in combination with TMZ could offer a new therapeutic opportunity for GBM target therapy. This evidence concerns the gene PLD1 and cancer.